Press Releases
Cook Medical’s Ongoing Drug-Eluting Peripheral Stent Trial Shows Consistent Outcomes
An investigational drug-eluting stent (DES) from Cook Medical showed sustained primary patency at two years compared to data collected at one year in the device’s prospective, randomized study, according to data presented today at the ISET 2010 International Symposium...
Press Releases
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments
Boehringer Ingelheim and Eli Lilly and Company announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents—linagliptin and BI10773—as well as...
Press Releases
Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab
Sandoz announced today that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera), a leading monoclonal antibody indicated in conditions including non-Hodgkin's lymphoma and rheumatoid arthritis. The phase...
Press Releases
Whats on the horizon for pharma sales- a look to the year ahead from UCB, Sanofi-Aventis & Actelion
eyeforpharma recently interviewed: Hans Hoogkamer, Business and Science Affairs, Actelion Pharmaceuticals, Daniel Ghozzi, Managing Director CIS, UCB Pharma Russia & Rune Pilegaard Associate Director, Business Support Nordics Sanofi-Aventis to see what they will be focusing on for the next...
Press Releases
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse Capsules
Shire plc, the global specialty biopharmaceutical company, today announced results from a study of Vyvanse®, assessing its effect in a model for Excessive Daytime Sleepiness (EDS). Vyvanse is a prescription medicine currently approved in the US, Canada and Brazil...
Press Releases
Merck Expand Study Investigating Erbitux as 1st Line Treatment in Advanced Gastric Cancer Completes Recruitment
Merck KGaA announced that recruitment has been completed for the pivotal Phase III EXPAND(a) clinical trial investigating the efficacy of Erbitux® (cetuximab) in treating patients with advanced gastric cancer. The international study has recruited more than 870 patients since...
Press Releases
KOMBIGLYZE XR Tablets, a New Treatment for Type 2 Diabetes Mellitus in Adults, Now Available in U.S. Pharmacies
Bristol-Myers Squibb Company and AstraZeneca announced that KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
